In collaboration with the Soham Foundation, the initiative focused on perimenopause, menopause, and hormone replacement therapy awareness at BESCOM’s Bengaluru headquarters.
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
The recommendation covers FYLREVY 14.2 mg and 18.9 mg for non-hysterectomised postmenopausal women experiencing oestrogen deficiency symptoms at least 12 months after their last menses
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
Acute therapies continue to report strong growth compared to chronic ones.
Subscribe To Our Newsletter & Stay Updated
